A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506499-29-00

Acronym

IGM-2323-101

Enrollment

Registered

2024-01-22

Start date

2024-02-28

Completion date

2025-01-27

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026